Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BHSTNASDAQ:CTNMNASDAQ:GNLXOTCMKTS:HSTC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHSTBioHarvest Sciences$6.84-5.0%$6.35$4.66▼$7.86$112.35M0.5816,708 shs12,375 shsCTNMContineum Therapeutics$4.29-3.2%$4.20$3.35▼$22.00$110.99M0.5287,370 shs71,121 shsGNLXGenelux$3.23+5.6%$2.59$1.60▼$5.89$121.88M-0.49191,334 shs447,722 shsHSTCHST Global$0.51$0.78$0.23▼$1.11$29.58M-1.061,185 shsN/A20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHSTBioHarvest Sciences0.00%+3.45%+10.77%+21.21%+719,999,900.00%CTNMContineum Therapeutics0.00%-6.74%+26.21%-37.25%-72.31%GNLXGenelux0.00%+19.53%+23.39%-17.96%+29.66%HSTCHST Global0.00%-38.31%-38.31%-37.56%-47.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHSTBioHarvest SciencesN/AN/AN/AN/AN/AN/AN/AN/ACTNMContineum Therapeutics2.5546 of 5 stars3.63.00.00.02.70.80.6GNLXGenelux1.1882 of 5 stars3.60.00.00.02.50.00.0HSTCHST GlobalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHSTBioHarvest Sciences 3.00Buy$13.6799.81% UpsideCTNMContineum Therapeutics 3.20Buy$22.50424.48% UpsideGNLXGenelux 3.20Buy$17.75449.54% UpsideHSTCHST Global 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest HSTC, BHST, GNLX, and CTNM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025CTNMContineum TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$25.00 ➝ $20.005/15/2025CTNMContineum TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$31.00 ➝ $31.005/8/2025GNLXGeneluxBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSpeculative Buy ➝ Speculative Buy$25.00 ➝ $23.005/5/2025BHSTBioHarvest SciencesCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.004/8/2025BHSTBioHarvest SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.003/31/2025GNLXGeneluxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/25/2025GNLXGeneluxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHSTBioHarvest Sciences$27.70M4.06N/AN/A($1.08) per share-6.33CTNMContineum Therapeutics$50M2.22$0.68 per share6.35($3.72) per share-1.15GNLXGenelux$8K15,235.51N/AN/A$0.73 per share4.42HSTCHST GlobalN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHSTBioHarvest Sciences-$12.56M-$0.50N/AN/AN/A-76.65%N/A-85.16%8/14/2025 (Estimated)CTNMContineum Therapeutics$22.72M-$1.97N/AN/AN/AN/A-49.92%-20.52%8/12/2025 (Estimated)GNLXGenelux-$28.30M-$0.88N/AN/AN/AN/A-105.05%-80.16%8/13/2025 (Estimated)HSTCHST Global-$150K-$0.02N/A∞N/AN/A-13,072.91%-31.66%N/ALatest HSTC, BHST, GNLX, and CTNM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025BHSTBioHarvest Sciences-$0.15-$0.13+$0.02-$0.13$8.93 million$7.64 million5/14/2025Q1 2025CTNMContineum Therapeutics-$0.56-$0.62-$0.06-$0.62$7.50 millionN/A5/8/2025Q1 2025GNLXGenelux-$0.24-$0.21+$0.03-$0.21N/AN/A3/31/2025Q4 2024BHSTBioHarvest Sciences-$0.12-$0.17-$0.05-$0.17$7.24 million$7.17 million3/28/2025Q4 2024GNLXGenelux-$0.17-$0.26-$0.09-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHSTBioHarvest SciencesN/AN/AN/AN/AN/ACTNMContineum TherapeuticsN/AN/AN/AN/AN/AGNLXGeneluxN/AN/AN/AN/AN/AHSTCHST GlobalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHSTBioHarvest SciencesN/A0.800.48CTNMContineum TherapeuticsN/A37.0637.06GNLXGeneluxN/A6.476.47HSTCHST GlobalN/A0.250.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHSTBioHarvest SciencesN/ACTNMContineum TherapeuticsN/AGNLXGenelux37.33%HSTCHST GlobalN/AInsider OwnershipCompanyInsider OwnershipBHSTBioHarvest SciencesN/ACTNMContineum Therapeutics11.30%GNLXGenelux9.30%HSTCHST Global65.82%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHSTBioHarvest SciencesN/A16.43 millionN/AN/ACTNMContineum Therapeutics3125.87 millionN/AN/AGNLXGenelux1037.74 million31.33 millionNot OptionableHSTCHST Global157.77 million16.33 millionNot OptionableHSTC, BHST, GNLX, and CTNM HeadlinesRecent News About These CompaniesHSTC HST Global, Inc.May 31, 2025 | seekingalpha.comHST Global Delays Yearly Report FilingApril 2, 2025 | tipranks.comHST Global Delays Form 10-K FilingMarch 31, 2025 | tipranks.comHST Global Inc HSTCNovember 15, 2024 | morningstar.comGST/HST Credit September 2024: Check Eligibility, Payment Dates & ScheduleOctober 2, 2024 | southarkansassun.comGST/HST Credit September 2024: Check Eligibility, Payment Dates & ScheduleOctober 2, 2024 | southarkansassun.comCanadians will soon receive GST/HST credit payments. How much?October 2, 2024 | msn.comCanadians will soon receive GST/HST credit payments. How much?October 2, 2024 | msn.comHost Hotels & Resorts, Inc (HST): Navigating Economic Cycles with Strategic ResilienceSeptember 26, 2024 | msn.comCKNW homepageSeptember 6, 2024 | globalnews.caVinaconex Investment and Tourism Development JSCSeptember 6, 2024 | morningstar.comLof International Dairy Products JSCSeptember 5, 2024 | morningstar.comHung Hau Agricultural Corp.August 31, 2024 | wsj.comHST Global Announces Details of Protocol Licensing for Health Matters InternationalAugust 19, 2024 | br.advfn.comViettel Global Investment JSC VGIMay 16, 2024 | morningstar.comGlobal Electrical Technology Corp.May 7, 2024 | wsj.comGlobal Surgery TrackApril 13, 2024 | bcm.eduViettel Global Investment JSCFebruary 23, 2024 | morningstar.comVNG Corp VNZFebruary 15, 2024 | morningstar.com2020 Land Rover Range Rover Sport ReviewDecember 17, 2023 | autoblog.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHSTC, BHST, GNLX, and CTNM Company DescriptionsBioHarvest Sciences NASDAQ:BHST$6.84 -0.36 (-5.00%) As of 03:59 PM EasternBioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.Contineum Therapeutics NASDAQ:CTNM$4.29 -0.14 (-3.16%) Closing price 04:00 PM EasternExtended Trading$4.28 -0.01 (-0.23%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.Genelux NASDAQ:GNLX$3.23 +0.17 (+5.56%) Closing price 04:00 PM EasternExtended Trading$3.28 +0.04 (+1.39%) As of 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.HST Global OTCMKTS:HSTC$0.51 0.00 (0.00%) As of 06/13/2025HST Global, Inc., operates as an integrated health and wellness biotechnology company in the United States. The company develops and/or acquires a network of wellness centers for the homeopathic and alternative treatment of late stage cancer and other life threatening diseases. It also focuses on the homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late stage cancer and or/ life threatening diseases. HST Global, Inc. is headquartered in Hampton, Virginia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore SoundHound’s AI Growth Story Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
